iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Treatment of cancer with allogeneic natural killer (NK) cell therapies has seen rapid development, especially use against hematologic malignancies. Clinical trials of NK cell-based adoptive transfer to treat relapsed or refractory malignancies have used peripheral blood, umbilical cord blood and plu...
Main Authors: | Benjamin H. Goldenson, Pooja Hor, Dan S. Kaufman |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.841107/full |
Similar Items
-
Next Generation Natural Killer Cells for Cancer Immunotherapy
by: Fiorella Rossi, et al.
Published: (2022-06-01) -
Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy
by: Sota Kurihara, et al.
Published: (2024-04-01) -
The EBiSC iPSC bank for disease studies
by: Rachel Steeg, et al.
Published: (2020-12-01) -
Suspension culture improves iPSC expansion and pluripotency phenotype
by: Nerea Cuesta-Gomez, et al.
Published: (2023-06-01) -
Human iPSC banking: barriers and opportunities
by: Ching-Ying Huang, et al.
Published: (2019-10-01)